Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 113 Madrid 106 Seville 47 Valencia 38 L'Hospitalet de Llobregat 35

Trials with a site in Madrid

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07630974Malignant Neoplasm

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

134

Esplugues de Llobregat, Madrid, Barcelona

2026-07-06

Recruiting

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

NCT07614984Lipoprotein(a)

DrugsHRS-5346·Enlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2

750

A Coruña, Castilleja de la Cuesta, Barcelona, Madrid, Seville

2026-06-30

Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471Follicular Lymphoma

DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2/3

960

Badalona, Málaga, Barcelona, Madrid, Salamanca

2026-06-22

Recruiting

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339Non-small Cell Lung Cancer

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Phase 3

310

Girona, Valencia, Barcelona, Madrid, Seville

2026-06-18

Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173B-cell Acute Lymphoblastic Leukemia

DrugsAvtozma·Tyenne·Siltuximab·MK-1045

Merck Sharp & Dohme LLC

Phase 2/3

340

Badalona, Madrid, Salamanca

2026-05-18

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Málaga, Badajoz, Madrid, Seville, Valencia

2026-05-04

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

DrugMK-1045

Merck Sharp & Dohme LLC

Phase 1/2

280

Badalona, Málaga, Barcelona, Madrid

2026-05-03

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Badalona, Santander, Las Palmas de Gran Canaria, Madrid, Barcelona, Seville

2026-04-23

Recruiting

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT07486960Psoriatic Arthritis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

140

Santiago de Compostela, Barcelona, Madrid, Valencia

2026-04-20

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Seville, L'Hospitalet de Llobregat, Madrid, Barcelona, Las Palmas, Valencia

2026-04-09

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Barcelona, Madrid

2026-03-23

Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib

Merck Sharp & Dohme LLC

Phase 3

400

Las Palmas de Gran Canaria, Girona, Majadahonda, Barcelona, Madrid, Málaga, Seville

2026-03-18

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Girona, A Coruña, Madrid, Valencia, Barcelona, Córdoba

2026-02-16

Recruiting

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

NCT07232602Bladder Cancer

DrugsMK-3120·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Barcelona, Madrid

2026-02-09

Recruiting

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

NCT07227597Small Cell Lung Cancer Extensive Stage

DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab

Merck Sharp & Dohme LLC

Phase 1/2

170

Logroño, Las Palmas de Gran Canaria, Barcelona, Madrid

2026-01-29

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703Cervical Cancer

DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin

Merck Sharp & Dohme LLC

Phase 3

1,023

Girona, Valencia, Barcelona, Córdoba, Madrid

2026-01-19

Recruiting

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection

DrugB/F/TAF

Merck Sharp & Dohme LLC

Phase 2/3

570

Madrid, Valencia, Barcelona, Málaga

2025-12-18

Recruiting

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT07247110Malignant Neoplasm

DrugsCetuximab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

250

Barcelona, Madrid

2025-12-16

Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

NCT07221474Squamous Non-small Cell Lung Cancer

DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 2

180

Hospitalet, Jerez de la Frontera, Barcelona, Madrid, Seville

2025-12-12

Recruiting

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

NCT07222488Bladder Cancer, Urinary Bladder Neoplasms

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

Málaga, Madrid

2025-12-09

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

Málaga, Barcelona, Madrid

2025-12-04

Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan·Cabozantinib

Merck Sharp & Dohme LLC

Phase 3

904

L'Hospitalet de Llobregat, Santander, Girona, Madrid, Valencia, Barcelona, Córdoba

2025-11-26

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Badalona, Barcelona, A Coruña, Majadahonda, Valencia, Madrid, Seville

2025-10-08

Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596Malignant Neoplasm

DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole

Merck Sharp & Dohme LLC

Phase 2

250

L'Hospitalet de Llobregat, A Coruña, Madrid

2025-08-11

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Madrid, Barcelona

2025-07-20

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia

2025-07-16

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

L Hospitalet Del Llobregat, Madrid, Seville

2025-07-03

Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Barcelona, Madrid

2025-05-29

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2025-05-28

Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT06941272Malignant Neoplasm

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

Esplugues de Llobregat, Barcelona, Madrid

2025-05-26

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

L'Hospitalet de Llobregat, Girona, Barcelona, Córdoba, Madrid, Valencia

2025-05-22

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Santander, Santiago de Compostela, Majadahonda Madrid, Madrid, Barcelona, Córdoba, Lugo, Seville

2025-05-13

Recruiting

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085Carcinoma, Non-Small-Cell Lung

DrugsR-DXd·Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet de Llobregat, Madrid

2025-05-13

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Palma, Santander, Barcelona, Madrid, Seville, Toledo

2025-05-12

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

Marbella, Barcelona, Madrid, Seville, Toledo

2025-04-16

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

L'Hospitalet de Llobregat, Majadhonda, Madrid, Valencia, Barcelona, Málaga

2025-04-15

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Girona, Madrid, Valencia, Barcelona, Córdoba

2025-04-09

Active, closed

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

NCT06864169Gastrointestinal Cancer

DrugR-DXd

Merck Sharp & Dohme LLC

Phase 2

160

Badalona, Santander, Barcelona, Madrid

2025-04-01

Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907Non-small Cell Lung Cancer

DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid

2025-03-30

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga

2025-03-25

Recruiting

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635Breast Neoplasms, Breast Cancer

DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin

Merck Sharp & Dohme LLC

Phase 2

372

Badalona, Madrid, Córdoba

2025-03-20

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Seville, L'Hospitalet de Llobregat, Madrid, Valencia, Barcelona

2025-03-16

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

DrugIntismeran autogene

Merck Sharp & Dohme LLC

Phase 2

308

Sabadell, Las Palmas de Gran Canaria, Madrid, Seville

2025-03-11

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Eixample, L'Hospitalet de Llobregat, Madrid, Barcelona, Málaga

2025-02-27

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

NCT06637423Non-Muscle Invasive Bladder Cancer

DrugSacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

Málaga, Madrid

2024-12-20

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Elche, Badalona, Centelles, Barcelona, A Coruña, Cartagena, Madrid, Seville

2024-12-02

Active, closed

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694Gastrointestinal Cancer

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

180

Oviedo, Barcelona, Madrid

2024-11-03

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Canarias, A Coruña, Pozuelo de Alarcón, Barcelona, Madrid, Málaga

2024-10-21

Active, closed

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory

Drugs) Berahyaluronidase alfa·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet Del Llobregat, Salamanca, Madrid

2024-10-14

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Esplugas de Llobregat, Madrid, Valencia, Barcelona

2024-08-16

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Córdoba

2024-07-24

Active, closed

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Barcelona, Madrid

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca

2024-07-16

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

Madrid, Oviedo, Barcelona

2024-06-20

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville

2024-06-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Badalona, Barcelona, A Coruña, Majadahonda, Torrejón de Ardoz, Madrid, Pontevedra, Santa Cruz de Tenerife

2024-06-05

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville

2024-05-24

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

L'Hospitalet de Llobregat, Madrid, Barcelona

2024-05-20

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Santander, A Coruña, Pamplona, Oviedo, Barcelona, Madrid

2024-05-03

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Córdoba, Seville

2024-04-14

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Madrid, Barcelona, Seville

2024-04-10

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

L'Hospitalet de Llobregat, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Barcelona, Madrid

2024-04-03

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Badalona, Pozuelo de Alarcón, Madrid, Barcelona, Seville

2024-03-28

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Jerez de la Frontera, Madrid, Ourense, Valencia, Lugo, Seville

2023-12-31

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga

2023-12-31

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Jerez de la Frontera, A Coruña, Pozuelo de Alarcón, Málaga, Valencia, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-15

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Barcelona, Córdoba

2023-12-06

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Barcelona, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Madrid, Málaga

2023-11-12

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Badalona, Terrassa, Galdakao-Usansolo, Fuenlabrada, Madrid, Torrejón de Ardoz, Valencia

2023-10-25

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Barcelona, Pozuelo de Alarcón, Madrid, Málaga, Valencia

2023-07-19

Active, closed

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

L'Hospitalet de Llobregat, Madrid, Barcelona, Seville

2023-07-06

Active, closed

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms

DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

390

Barcelona, Madrid

2023-06-23

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Esplugues de Llobregat, Barcelona, A Coruña, Madrid, Seville

2023-05-31

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

Elche, Badalona, Barcelona, L'Hospitalet de Llobregat,Barcelona, Madrid, Málaga

2023-03-08

Active, closed

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015Metastatic Non-small Cell Lung Cancer

DrugsPegylated filgrastim·Pembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol

Merck Sharp & Dohme LLC

Phase 3

377

Santiago de Compostela, Madrid, Barcelona, Huelva

2023-02-14

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Madrid, Valencia, Barcelona

2023-01-19

Recruiting

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830Urothelial Carcinoma

DrugsMK-3120·Zilovertamab vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Barcelona, Madrid

2022-11-16

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

L'Hospitalet Del Llobregat, Barcelona, Madrid, Pamplona, Salamanca

2022-07-21

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401Lymphoma, Large B-Cell, Diffuse (DLBCL)

DrugsRituximab Biosimilar·Zilovertamab vedotin·Truxima·Adriamycin

Merck Sharp & Dohme LLC

Phase 2

Seville, L'Hospitalet Del Llobregat, Madrid

2022-07-14

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Madrid, Málaga, Barcelona, Seville

2022-03-24

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Girona, Madrid, Valencia, Barcelona, Lugo, Málaga

2022-03-15

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Madrid, Barcelona

2021-12-17

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Elche, Badalona, Barcelona, Madrid

2021-09-15

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Badalona, Santiago de Compostela, Madrid, Oviedo, Barcelona

2021-08-18

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Madrid, Oviedo, Barcelona

2021-08-12

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Santander, Barcelona, Madrid, Málaga, Pamplona, Oviedo, Valencia

2021-06-25

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Barcelona, Pozuelo de Alarcón, Madrid, Valencia

2021-06-18

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Palma de Mallorca, Santander, Barcelona, Majadahonda, Madrid, Toledo

2021-05-12

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

1,688

Santander, Barcelona, Girona, Madrid, Málaga

2021-04-14

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

DrugNemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

490

L'Hospitalet de Llobregat, Salamanca, A Coruña, Alicante, Barcelona, Madrid

2021-04-05

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231Carcinoma, Renal Cell

DrugsBelzutifan·Cabozantinib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

747

A Coruña, Madrid, Barcelona, Seville

2021-02-25

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Girona, Madrid, Barcelona, Córdoba

2021-01-10

Active, closed

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204Small Cell Lung Cancer

DrugsOlaparib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

672

L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Málaga, Seville

2020-12-08

Active, closed

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750Carcinoma, Renal Cell

DrugsBelzutifan·Everolimus

Merck Sharp & Dohme LLC

Phase 3

755

Barcelona, Valencia, Madrid

2020-02-27

Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070Carcinoma, Non-Small-Cell Lung

DrugsMK-4830·Ifinatamab Deruxtecan·Patritumab deruxtecan·Abraxane

Merck Sharp & Dohme LLC

Phase 1/2

450

L'Hospitalet de Llobregat, Madrid

2019-12-19

Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798Carcinoma, Non-Small-Cell Lung

Merck Sharp & Dohme LLC

Observational

1,065

L'Hospitalet de Llobregat, Barcelona, Madrid

2019-12-19

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Badalona, Barcelona, Cáceres, Girona, Pozuelo de Alarcón, Valencia, Madrid, Seville

2019-07-24

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

L'Hospitalet de Llobregat, A Coruña, Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Jaén, Seville

2018-12-27

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032High-risk Non-muscle Invasive Bladder Cancer

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,397

Lugo, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Valencia

2018-12-24

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Barcelona, Madrid, Seville

2018-12-17

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Donostia / San Sebastian, Valencia, Barcelona, Madrid, Seville

2018-09-12

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643Non-small Cell Lung Cancer

DrugsPemetrexed·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

797

Badalona, L'Hospitalet de Llobregat, Girona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville

2018-04-24

Active, closed

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

NCT03407144Hodgkin Lymphoma

DrugsPrednisone/Prednisolone·Vinblastine·Bleomycin·Dacarbazine

Merck Sharp & Dohme LLC

Phase 2

340

Barcelona, Madrid

2018-04-09

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 106 of those studies with a site in Madrid that also match the filters currently applied.

How many clinical trials are recruiting in Madrid?

64 of the 106 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 42 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Madrid), 106 studies
Phase	Studies	Recruiting	Share
Phase 3	53	26	50%
Phase 2	24	14	22.6%
Phase 1/2	21	17	19.8%
Phase 2/3	4	4	3.8%
Phase 1	3	2	2.8%
Observational	1	1	0.9%

Most active sponsors

Lead sponsors with the most studies (Madrid)
Lead sponsor	Studies	Recruiting
Merck Sharp & Dohme LLC	106	64

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.